{"filing":{"accession_number":"0001104659-26-088481","cik":"0001737953","ticker":"REPL","company_name":"Replimune Group, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"tm2621663d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926088481/tm2621663d1_8k.htm"},"events":[{"id":22122,"run_id":19991,"accession_number":"0001104659-26-088481","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Replimune disclosed attendance at an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting on July 30, 2026, to discuss a BLA resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma treatment. This is a material regulatory milestone for a clinical-stage biopharmaceutical company—the advisory committee meeting represents a critical juncture in the FDA approval process for a breakthrough-designated therapy. While not a formal approval or denial, the meeting and supporting presentation materials constitute a significant operational and regulatory event that would affect investor assessment of the company's pipeline progress and near-term catalysts.","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21973,"accession_number":"0001104659-26-088481","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Replimune disclosed attendance at an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting on July 30, 2026, to discuss a BLA resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma treatment. This is a material regulatory milestone for a clinical-stage biopharmaceutical company—the advisory committee meeting represents a critical juncture in the FDA approval process for a breakthrough-designated therapy. While not a formal approval or denial, the meeting and supporting presentation materials constitute a significant operational and regulatory event that would affect investor assessment of the company's pipeline progress and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T12:07:41.567544+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21973,"accession_number":"0001104659-26-088481","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Replimune disclosed attendance at an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting on July 30, 2026, to discuss a BLA resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma treatment. This is a material regulatory milestone for a clinical-stage biopharmaceutical company—the advisory committee meeting represents a critical juncture in the FDA approval process for a breakthrough-designated therapy. While not a formal approval or denial, the meeting and supporting presentation materials constitute a significant operational and regulatory event that would affect investor assessment of the company's pipeline progress and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T12:07:41.567544+00:00","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-07-30"}]}